Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a retrospective study encompassing all [18F]FET PET scans performed at our centre. By analysing both static and dynamic scans, conducting in-depth kinetic modelling, and comparing quantitative parameters across different tumour types and clinical contexts, the study aims to determine the true diagnostic value of [18F]FET PET in everyday clinical practice. The ultimate goal is to identify imaging biomarkers useful for improving tumour characterisation and distinguishing recurrence from post-treatment changes, thereby strengthening the role of [18F]FET PET in modern neuro-oncology.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with brain tumors | Patients with gliomas, brain metastases and meningiomas |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Primary outcome | Diagnostic accuracy of [18F]FET PET (static and dynamic PET/CT or PET/MR) in differentiating tumor recurrence from treatment-related changes, using a composite reference standard including histopathological data (when available) and clinical-radiological follow-up. | Retrospective analysis of data acquired up to December 31, 2025. |
| Measure | Description | Time Frame |
|---|---|---|
| Secondary Outcome Measure | Quantification and clinical utility of static [18F]FET PET parameters in tumor characterization. | Up to December 31, 2025. |
| Diagnostic Outcome Measure | Diagnostic performance of quantitative [18F]FET PET parameters in differentiating tumor types and clinical categories (high-grade vs low-grade gliomas, primary brain tumors vs metastases, and histological subtypes). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patients (≥18 years) who underwent clinically indicated [18F]FET PET/CT or PET/MR brain scans for evaluation of primary or metastatic brain tumors, including diagnosis, grading, treatment response assessment, or suspected recurrence.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Chiara Catalano, PhD | Contact | +39 0226433639 | catalano.chiara@hsr.it; ricercamednuc@hsr.it | |
| Alexandra Lazar, Dr. | Contact | lazar.alexandra@hsr.it; |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001932 | Brain Neoplasms |
| D008579 | Meningioma |
| ID | Term |
|---|---|
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Up to December 31, 2025. |
| Quantitative outcome | Correlation of quantitative [18F]FET PET metrics with imaging biomarkers from other modalities and added value of kinetic modeling. | Up to December 31, 2025. |
| Secondary Outcome Measure | Quantification and clinical utility of dynamic [18F]FET PET parameters in tumor characterization | Up to December 31, 2025 |
| Secondary Outcome Measure | Quantification and clinical utility of kinetic and parametric [18F]FET PET in tumor characterization | Up to December 31, 2025. |
| D001927 |
| Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D009380 | Neoplasms, Nerve Tissue |
| D009370 | Neoplasms by Histologic Type |
| D009383 | Neoplasms, Vascular Tissue |
| D008577 | Meningeal Neoplasms |